Connect with us

Medicinal

Mushroom healing with Silo Wellness and the Bob Marley family

The Marley One functional mushroom products have been developed in collaboration with the family of legendary musician Bob Marley.

Published

on

Mushroom healing with Silo Wellness and the Bob Marley family

The company that launched the world’s first psilocybin nasal spray, Silo Wellness, is on a mission to bring healing through psychedelic and functional mushrooms with the launch of its Marley One product range.

Silo Wellness is focusing on creating products that can provide alternative options for healing – with the launch of the world’s first psilocybin nasal spray from its facilities in Jamaica, where the compound is legal, and now with the world’s first functional and psychedelic mushroom supplement range.

The Marley One functional mushroom products have been developed in collaboration with the family of legendary musician Bob Marley to honour his holistic wellness beliefs and connection to nature.

Functional mushrooms for the people

The Marley One range utilises functional, non-psychoactive mushrooms tinctures designed to enhance focus, cognitive function, gut health, immunity, sleep and more, and will later be expanded to include psychedelic products to help meet mental health needs.

Cedella Marley, Bob Marley’s daughter, three-time Grammy winner, author, mother and CEO of Bob Marley Group of Companies, has had a major input into the development of the tinctures.

Mushroom healing with Silo Wellness and the Bob Marley family

Douglas K. Gordon of Silo Wellness and Cedella of Marley One.

Speaking to Psychedelic Health, Silo Wellness CEO, Douglas Gordon, said: “There’s a lot of data and research about functional mushrooms and their benefits. We really have leveraged that with our formulation team, and we have added other active ingredients that people are more familiar with, like ginkgo and ginger that have other health benefits.

“In our research process, we ensured that the products would have accretive benefits. For some people, they have heard of lion’s mane, turkey tail, chaga, but they don’t know the category of function mushrooms, and this is why we put the different ingredients – for additional health benefits but also to integrate familiarity for the consumer who is new to the category.

“The taste of functional medicines also tends to be medicinal – so, we looked at how to make them more palatable, and at the same ensure that with our heritage out of Jamaica, and therefore very Caribbean, how do we get a taste palate that also you know incorporated our geography. So, we have done a lot of testing and utilised a tremendous amount of expertise thanks to smart people who know how to mix and combine these different ingredients.

“Our collaboration with the Marley family allows us to do functional and psychedelic mushrooms, and we are now in the process of R&D around some psychedelic formulations that will launch in jurisdictions where it is fully legal. There is a number of different species of psilocybin mushrooms, and looking at this is a part of our R&D – understanding which particular strains of the fungi we want to utilise in each of the different products.”

See also  Marley One mushrooms to hit UK market through distribution agreement

Gordon says that Silo’s psilocybin nasal spray has provided a proof-of-concept for delivery modality.

“We have been active in talking to different pharmaceutical entities who are looking for delivery modalities and that’s where our nasal spray holds an interesting position. We’re looking at not just developing our own commercially viable line in that regard, but also to be able to licence out the technology to other companies that are looking for that, for their own progress.

“Our collaboration is with the estate of Bob Marley and Rita Marley herself was instrumental with the flavours and with getting feedback on that process. It has been very interesting, illuminating and exciting but it has also been grounded in a very real and authentic relationship where the family is very much in tune with what they put their name on and what they endorse. They’ve been extremely supportive in terms of understanding the health benefits of mushrooms, both functional and psychedelic, and the opportunity this provides to really help many people around the world.”

Helping people in the here and now

Gordon says that Silo Wellness is focused on helping people as soon as possible and to achieve this aim, it is combining ancient wisdom and modern science to unlock people’s potential and help them realise greater self-actualisation.

“Silo Wellness is very focused on helping people right now – a lot of companies are doing incredible research that once it’s successful, they’re able to bring drugs to market that can help folks, and that is fantastic – but that is five to seven years out. What we have done is taken our traditional, very straight line clinical medical approach and also learnt so much from what indigenous cultures have done which have been using psychedelics for a very long time. That has helped us to be very effective in terms of mindfulness and expansive traditional uses.

“We want to do that because, what we’ve seen with our retreats, for example, is that folks have had transformative experiences and it’s a very powerful testimonial as a validation of our whole underlying business ethos because we want to help people today.

“For us, if we can help someone now – let’s help them now. If we can help more people later, when there are more legal jurisdictions, that’s absolutely wonderful, but we do have the ability, the desire and enterprise to help people now, and that’s what motivates us.

“The great thing about the Marley collaboration and the introduction of our functional mushroom products is that there is no psychedelic impact whatsoever and so in the process, you start to stimulate conversation that will destigmatise mushrooms from the psychedelic side. And it’s so powerful and so incredibly important because while we have huge ambitions for Marley One we know that the real transformative impact that mushrooms have is psychedelic and it is also helping people in the short term by giving natural, healthy substitutes and supplements and their diets and lifestyles. It is a tool to pave the pathway for more people to be comfortable using psychedelics in the future.

“… the natural compounds that come out of the Earth have tremendous healing powers for us as humans.”

“I was involved in the cannabis space from 2016 when I founded a conference here in Jamaica, Called CanEx Jamaica, which was oriented around providing a platform for professionals and experts from around the world and in Jamaica to get together, network and exchange knowledge, and to help to build the industry.

“When your mind opens to understanding the immense power of plant medicine, and again, this comes back to Bob Marley – he spoke so often about one love – my interpretation of One Love was that whether you’re black, white, Jamaican, American, Canadian, whatever, we’re all one people, one species, and we should therefore be able to love one another without artificial barriers.

“But, with psychedelics, what they allowed me to see is that the notion of oneness really goes beyond us as humans being one. It really espouses the notion that we have the ability, the Earth has the ability, to heal itself, and that the natural compounds that come out of the Earth have tremendous healing powers for us as humans.

“For too long we’ve always thought we were the most superior species walking the face of the Earth, not realising that a lot of the wonderful ideas we have are actually undermining the viability of the Earth. What we now have is the opportunity to see with psychedelics the healing that we as humans are in need of – because we’re not living our full experiences, we have traumas, we have mental health issues, we have PTSD, anxiety – what people think of you and all of these different things that social media exacerbates. We have the ability to reframe and rewire our own neural pathways, just by virtue of natural compounds that have turned up here on the Earth.

“So, that whole idea of oneness, has really broadened for me. And, the opportunity to lead Silo Wellness was a very simple decision.

“What was interesting to me was the fact that this company seemed anchored around helping people and it allowed me to lead a company that was young, ambitious and with some great people attached to it. I have great admiration for the founders and the energy that went into founding this, to bring this company to life. But I think at the core of it is the fact that we have these wonderful products that allow us to build this business and help a lot of people in the process. What we’re doing, I believe, is for the right reasons. And we’re doing it in the right way.”

The company has recently reached agreements to stock its functional mushroom products in the UK and further functional products are set to follow, including gummies, capsules and cosmetics.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Medicinal

MDMA for PTSD receives priority review for New Drug Application

Published

on

Photo by iStrfry , Marcus on Unsplash

Lykos Therapeutics, formerly MAPS Public Benefit Corporation, has announced it has received FDA acceptance and priority review for a New Drug Application (NDA) concerning its MDMA-assisted therapy for PTSD.

The FDA has accepted Lykos’s NDA for MDMA capsules used in combination with psychological intervention. This intervention includes psychotherapy and other supportive services provided by a qualified healthcare provider for individuals with PTSD. 

Lykos has stated that the FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 11, 2024. Current statistics show that 89% of applications that meet their PDUFA deadline are approved. If this application is approved, it would make this the first MDMA-assisted therapy and psychedelic-assisted therapy.

In a press statement, Amy Emerson, chief executive officer of Lykos Therapeutics, commented: “Securing priority review for our investigational MDMA-assisted therapy is a significant accomplishment and underscores the urgent unmet need for new innovation in the treatment of PTSD.

“We remain focused on working with the FDA through the review process and preparing for a controlled launch with an emphasis on quality should this potential treatment be approved.”

The NDA submission was supported by results from several studies on the therapy, including two Phase 3 studies that looked at the efficacy and safety of the therapy. Both of these studies met their primary endpoints, which were a change in PTSD symptom severity and an improvement in functional impairment associated with PTSD. 

While no serious adverse events were reported in the MDMA group in either study, Lykos highlights that the safety and efficacy of MDMA-assisted therapy have not been established for the treatment of PTSD.

The news has been welcomed across the pond by European campaign groups advocating for access to psychedelic-assisted therapy. 

In a press statement, campaign group PAREA commented: “Innovation in mental health has stagnated for decades. In the past three years, Europe has approved only one new psychiatric treatment, compared to 68 in oncology. 

“While the U.S. is on the brink of approving the first psychedelic-assisted therapy, Europe significantly lags behind. This is primarily because the current incentives and rewards for companies to conduct large-scale pivotal trials on psychedelics are insufficient in Europe, highlighting the need for enhanced support and incentives to advance novel mental health treatments.”

While the US makes strides in advancing psychedelic healthcare, Europe is now beginning to take note of this scientific development, with the European Medicines Agency (EMA) set to hold a multi-stakeholder workshop on medical psychedelics in April 2024.

The workshop aims to establish regulatory guidelines for the development and therapeutic use of psychedelic substances in Europe.

The continent also made a recent historic advancement in the field of psychedelic research. In January 2024, the European Union announced €6.5 million in funding for research into psychedelic therapy as part of its Horizon Europe programme. 

The funding has been awarded to a consortium of 19 partners from nine different European countries for a clinical trial – the PsyPal trial – which will study psilocybin-assisted psychotherapy for psychological and existential distress in people who are diagnosed with either chronic obstructive pulmonary disorder (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) or atypical Parkinson’s disease (APD). 

Continue Reading

Medicinal

Doctors warn against potentially harmful psychedelic “trip killers”

Published

on

Photo by Altin Ferreira on Unsplash

Doctors have raised a warning against so-called “trip killers” that are used to end challenging psychedelic experiences on compounds such as LSD or psilocybin.

The doctors have published the warning in a letter in the Emergency Medicine Journal. In the letter, an analysis of relevant Reddit threads is provided that show drugs such as benzodiazepines and antipsychotics recommended to help end these challenging psychedelic experiences. However, the doctors emphasise that these recommendations rarely include information about potential side effects.

A total of 128 Reddit threads created were discovered that were created between 2015 and 2023, yielding a total of 709 posts. With 440 recommendations, amounting to nearly half – 46% – of all the ‘trip-killers’ mentioned in posts, were various benzodiazepines, followed by several different antipsychotics at 171%.

See also  Mixing psychedelics with lithium poses significant risk of seizures

The team found that one in 10 recommendations were for antidepressants, while one in 20 were for alcohol. Opioids, antihistamines, herbal remedies, such as camomile and valerian, and prescribed sleeping pills, attracted 3% each, with cannabis and cannabidiol at 2%.

Trip-killers were mostly discussed in reference to countering the effects of LSD (235 recommendations), magic mushrooms (143), and MDMA (21). Only 58 posts mentioned potentially harmful side effects.

The authors write: “The popularity of benzodiazepines raises concerns. Benzodiazepines are addictive and have been repeatedly implicated in overdose deaths. 

“The doses described on Reddit risk over-sedation, hypotension [low blood pressure], and respiratory depression [stopping breathing or shallow breathing].”

Doses of one of the recommended antipsychotics, quetiapine, were also high the authors note, with only a few posts differentiating between fast and slower release formulations.

“Information on trip-killers isn’t available through drug advice services, despite the probable risks they pose,” highlight the authors.

Continue Reading

Medicinal

Integrating metaphysics into psychedelic therapy

Published

on

Integrating metaphysics into psychedelic therapy

Dr Peter Sjöstedt-Hughes, Lecturer at Exeter University, has proposed incorporating metaphysical philosophy into psychedelic therapy to help improve therapeutic outcomes.

Sjöstedt-Hughes suggests that psychedelic therapy may gain more advantage by extending its scope into metaphysics, helping patients better integrate and understand psychedelic-induced metaphysical experiences.

Such improved outcomes may be seen if patients undergoing this therapy “are provided with an optional, additional, and intelligible schema and discussion of metaphysical options at the integrative phase of the therapy.” 

See also  Study explores relationship between psychedelics and consciousness

In the paper, Sjöstedt-Hughes puts forward this schema as the “Metaphysics Matrix” and an accompanying “Metaphysics Matrix Questionnaire (MMQ)” which can be utilised by therapists and researchers as a tool for the quantitative measurement of a psychedelic experience.

The paper ‘On the need for metaphysics in psychedelic therapy and research’ has been published in Frontiers in Psychology.

What is metaphysics?

While mysticism deals with understanding the universe through direct experience, such as revelation, metaphysics is a branch of philosophy that deals with understanding the fundamental nature of reality through logic/argument.

See also  How consciousness may rely on brain cells acting collectively – new psychedelics research on rats

Sjöstedt-Hughes writes that “metaphysics is not mysticism” but there is overlap: “[…] metaphysics is broader and its positions can be logically deliberated — as such metaphysics can encompass mystical experiences induced by psychedelic intake yet metaphysics can also ground those experiences in a manner that can be more intelligible, comprehensive, viable, and acceptable to participants than that which the framework of mysticism alone can offer.”  

The Metaphysics Matrix

A number of clinical trials investigating psychedelic-assisted psychotherapy for the treatment of mental health conditions, such as anxiety and depression, report that participants who undergo a “mystical experience” during a psychedelic session often have higher levels of sustained therapeutic outcomes.

In clinical trials, mystical experiences are measured by different scales including the Mystical Experience Questionnaire (MEQ), the Hood Mysticism Scale (HMS), the Hallucinogen Rating Scale (HRS), the Five Dimensions Altered State of Consciousness Questionnaires (5D-ASC) and Eleven Dimensions Altered State of Consciousness Questionnaires (11D-ASC).

Sjöstedt-Hughes writes: “Data derived in this manner is obviously limited and abstract not only because psychedelic experience need not be “mystical,” but also because the definition of “mystical” could be expanded to include other criteria [

“With regard to psychedelic-assisted psychotherapy […] speaking about mystical experience per se will not be sufficient to provide a meaningful explanation of the significance of such experience to a person, for the simple reason that mystical experience is the phenomenon to be explained — mystical experience is the explanandum rather than the explanation. 

“It is metaphysics that is the means of explanation, the explanans of the mystical explanandum.”

The Metaphysics Matrix has been designed to provide a “menu” of metaphysical options that may help people to “frame, make sense of, and give significance to, their experiences”, and would be another tool in the belt of therapists to better understand these experiences.

Image provided by Dr Peter Sjöstedt-Hughes.

Such experiences could be understood through metaphysical systems such as Neutral Monism, Pantheism, Panpsychism, Animism, Substance Dualism, and Idealism, says Sjöstedt-Hughes. 

Some examples provided include the common experience of the Universe being God – which can be understood in the context of Pantheism – or of all matter having a basic form of sentience – such as plants having a basic drive or process – which can be understood in the context of Panpsychism. 

Image provided by Dr Peter Sjöstedt-Hughes.

Additionally, enabling people who have had these experiences to understand them within these frameworks may make them less likely to dismiss the experiences as delusional, says Sjöstedt-Hughes.

“ […] Relatedly, that the worldview hitherto adopted by the participant is but one metaphysical position amongst others,” he writes. 

Sjöstedt-Hughes commented: “This is a conjecture that hasn’t been tested but can be tested – offering a patient an additional and optional discussion in the integrative phase of psychedelic-assisted psychotherapy. 

“Giving them this Metaphysics Menu for integration may extend the long-term benefits of psychedelic therapy and beyond because there’s a number of studies that seem to show that certain peak psychedelic experiences have the longest and most beneficial health outputs results.

“If in the integrative phase [of therapy] one looks at that experience and starts to frame it intelligibly, then the conjecture is that the participant will not in a few weeks after that, think it must have been a delusion – they will say that we don’t know what reality is. 

“Therefore, we can’t dismiss something as a delusion necessarily. By doing that it might extend the significance of that experience for the person.

“When we use Mysticism Scales, by definition, mystery can’t explain itself. Metaphysics, however, incorporates those experiences and offers an explanation to what they mean. For example, the relation between oneself and the universe.”

Sjöstedt-Hughes points out that in practice, one of the immediate issues is the practical issue of implementation of Metaphysics Integration, suggesting this could be supported through resources such as a handbook or practitioner training.

He further concludes the integration would need to be “further bridged by the therapist to the participant’s life, concerns, values, aims, and outlook.”

The Metaphysics Schema is already being utilised in studies taking place at Ohio State University, US, and Exeter University, UK.

Continue Reading

Trending

Psychedelic Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. We do not provide medical advice or promote the personal use of psychedelic compounds. Please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 Psych Capital Plc